Market Overview

UPDATE: Wedbush Reiterates Outperform Rating, Raises PT on Chelsea Therapeutics International on Successful Appeal

Related CHTP
Chelsea Therapeutics Reports Clinical Trial Data on NORTHERA
JMP, Needham Doubtful Over Chelsea Therapeutics Receiving Additional Bids

In a report published Wednesday, Wedbush reiterated its Outperform rating on Chelsea Therapeutics International (NASDAQ: CHTP), and raised its price target from $5.00 to $7.00.

Wedbush noted, “Chelsea's apparently successful appeal to the Office of New Drugs may reduce regulatory risk for Northera. Recall that Chelsea is developing Northera, a pro-drug of norepinephrine, as a treatment for neurogenic orthostatic hypotension (NOH)—an acute drop in blood pressure which can result in dizziness and injuries due to falls. At the end of March 2012, Chelsea received a complete response letter (CRL) for Northera instead of approval. The focus of a new reviewer in the Division of Cardiovascular and Renal Products (DCRP) changed from the OHQ as a primary endpoint to the mixed results for dizziness and durability—also concluding that the then ongoing ‘306b Phase 3 trial was unsuitable as a basis for resubmitting the NDA. Chelsea subsequently successfully appealed to the bosses of DCRP in CDER's Office of New Drugs and Northera now has a shot at approval–potentially without conducting another Phase 3 trial prior. The FDA suggested that Chelsea should resubmit the NDA and include the ‘306b results, which they plan to do in late Q2 under a Class 2 review (6 months), which could provide a PDUFA deadline for a second DCRP approval decision around year-end 2013.”

Chelsea Therapeutics International closed on Tuesday at $1.47.

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Related Articles (CHTP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional